BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23569176)

  • 21. Inflammation and interleukin-6 mediate reductions in the hepatic expression and transcription of the mdr1a and mdr1b Genes.
    Sukhai M; Yong A; Kalitsky J; Piquette-Miller M
    Mol Cell Biol Res Commun; 2000 Oct; 4(4):248-56. PubMed ID: 11409920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
    Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gestational and pregnane X receptor-mediated regulation of placental ATP-binding cassette drug transporters in mice.
    Gahir SS; Piquette-Miller M
    Drug Metab Dispos; 2011 Mar; 39(3):465-71. PubMed ID: 21127142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disposition of the cholesterol absorption inhibitor ezetimibe in mdr1a/b (-/-) mice.
    Oswald S; Koll C; Siegmund W
    J Pharm Sci; 2007 Dec; 96(12):3478-84. PubMed ID: 17828742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.
    de Vries NA; Zhao J; Kroon E; Buckle T; Beijnen JH; van Tellingen O
    Clin Cancer Res; 2007 Nov; 13(21):6440-9. PubMed ID: 17975156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of genetic deficiencies of P-glycoprotein and breast cancer resistance protein on pharmacokinetics of aripiprazole and dehydroaripiprazole.
    Nagasaka Y; Sano T; Oda K; Kawamura A; Usui T
    Xenobiotica; 2014 Oct; 44(10):926-32. PubMed ID: 24666334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinct alterations in ATP-binding cassette transporter expression in liver, kidney, small intestine, and brain in adjuvant-induced arthritic rats.
    Kawase A; Norikane S; Okada A; Adachi M; Kato Y; Iwaki M
    J Pharm Sci; 2014 Aug; 103(8):2556-64. PubMed ID: 24912442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporin A absorption, and effect of dexamethasone in small intestine of mice.
    Jin M; Shimada T; Yokogawa K; Nomura M; Ishizaki J; Piao Y; Kato Y; Tsuji A; Miyamoto K
    Biochem Pharmacol; 2006 Oct; 72(8):1042-50. PubMed ID: 16939683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brain cyclosporin A levels are determined by ontogenic regulation of mdr1a expression.
    Goralski KB; Acott PD; Fraser AD; Worth D; Sinal CJ
    Drug Metab Dispos; 2006 Feb; 34(2):288-95. PubMed ID: 16303871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toxicological significance of renal Bcrp: Another potential transporter in the elimination of mercuric ions from proximal tubular cells.
    Bridges CC; Zalups RK; Joshee L
    Toxicol Appl Pharmacol; 2015 Jun; 285(2):110-7. PubMed ID: 25868844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sestamibi is a substrate for MDR1 and MDR2 P-glycoprotein genes.
    Joseph B; Bhargava KK; Malhi H; Schilsky ML; Jain D; Palestro CJ; Gupta S
    Eur J Nucl Med Mol Imaging; 2003 Jul; 30(7):1024-31. PubMed ID: 12536246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells.
    Karlsson JE; Heddle C; Rozkov A; Rotticci-Mulder J; Tuvesson O; Hilgendorf C; Andersson TB
    Drug Metab Dispos; 2010 Apr; 38(4):705-14. PubMed ID: 20071452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Morphological and functional changes in p-glycoprotein during dexamethasone-induced hepatomegaly.
    Micuda S; Fuksa L; Mundlova L; Osterreicher J; Mokry J; Cermanova J; Brcakova E; Staud F; Pokorna P; Martinkova J
    Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):296-303. PubMed ID: 17324141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds.
    Enokizono J; Kusuhara H; Ose A; Schinkel AH; Sugiyama Y
    Drug Metab Dispos; 2008 Jun; 36(6):995-1002. PubMed ID: 18322075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mdr1a, Bcrp and Mrp2 regulate the efficacy and toxicity of mesaconitine and hypaconitine by altering their tissue accumulation and in vivo residence.
    Li X; Ou X; Luo G; Ou X; Xie Y; Ying M; Qu W; Zuo H; Qi X; Wang Y; Liu Z; Zhu L
    Toxicol Appl Pharmacol; 2020 Dec; 409():115332. PubMed ID: 33171190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib.
    Oostendorp RL; Buckle T; Beijnen JH; van Tellingen O; Schellens JH
    Invest New Drugs; 2009 Feb; 27(1):31-40. PubMed ID: 18449471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and human.
    Kalgutkar AS; Feng B; Nguyen HT; Frederick KS; Campbell SD; Hatch HL; Bi YA; Kazolias DC; Davidson RE; Mireles RJ; Duignan DB; Choo EF; Zhao SX
    Drug Metab Dispos; 2007 Nov; 35(11):2111-8. PubMed ID: 17686907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP.
    Xiao L; Yi T; Chen M; Lam CW; Zhou H
    Eur J Pharm Sci; 2016 Oct; 93():456-67. PubMed ID: 27586020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
    Graber-Maier A; Gutmann H; Drewe J
    Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decreased hepatic breast cancer resistance protein expression and function in multidrug resistance-associated protein 2-deficient (TR⁻) rats.
    Yue W; Lee JK; Abe K; Sugiyama Y; Brouwer KL
    Drug Metab Dispos; 2011 Mar; 39(3):441-7. PubMed ID: 21106720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.